Publications by authors named "Adera Mathews"

Claim this Profile
G
Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study.
Christopher Keary, Lynne M Bird, Marie-Claire de Wit, Shivkumar Hatti, Gali Heimer, Adera Mathews

Eur J Paediatr Neurol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study.
Dejan B Budimirovic, Kelli C Dominick, Lidia V Gabis, Maxwell Adams, Mathews Adera

Front Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an adapted Clinical Global Impression scale for use in Angelman syndrome.
Alexander Kolevzon, Pamela Ventola, Christopher J Keary, Gali Heimer, Jeffrey L Neul, Mathews Adera

J Neurodev Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in Stable Patients With Schizophrenia.
Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwarz

Clin Pharmacol Drug Dev· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.
Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwarz

Psychopharmacol Bull· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1, Open-Label, Single Dose Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.
Ryan Dammerman, Sonnie Kim, Mathews Adera, Alex Schwarz

Psychopharmacol Bull· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Mathews Adera

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers.
Franklin K Johnson, Paul N Mudd, Alexander Bragat, Mathews Adera, Pol Boudes

Clin Pharmacol Drug Dev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
Michael McClung, Robert Recker, Paul Miller, Darrell Fiske, Jerome Minkoff, Mathews Adera

Bone· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis